Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double blind, randomised, placebo controlled, multicentre trial of anti-tumour necrotising factor alpha (anti-TNF alpha) chimeric monoclonal antibody (infliximab, Remicade) in combination with methotrexate in patients with very early inflammatory arthritis

Next Previous
X
Search
Trial Profile

A double blind, randomised, placebo controlled, multicentre trial of anti-tumour necrotising factor alpha (anti-TNF alpha) chimeric monoclonal antibody (infliximab, Remicade) in combination with methotrexate in patients with very early inflammatory arthritis

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 06 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Infliximab (Primary) ; Methotrexate
  • Indications Arthritis
  • Focus Therapeutic Use
  • Acronyms DINORA

    • Most Recent Events

    • 17 Jun 2017 Results (n=90) presented at the 18th Annual Congress of the European League Against Rheumatism
    • 06 Nov 2010 Additional trial investigator (Scott DL) added as reported by United Kingdom Clinical Research Network record.
    • 23 Sep 2010 Planned end date changed from 15 Sep 2011 to 1 Jul 2012 as reported by United Kingdom Clinical Research Network record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top